Famous Patents
The first match was accidentally discovered in 1826 when John Walker scraped a stick with chemicals on the end against a stone floor.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120045468 | Immunogenic Compositions and Uses Thereof Disclosed are methods of producing a purified EV71 virus antigen. Also disclosed are related immunogenic compositions and immunization methods.... | 02/23/2012 |
| 20120040891 | HIV FUSION INHIBITOR PEPTIDES WITH IMPROVED BIOLOGICAL PROPERTIES Provided is an HIV fusion inhibitor peptide having an amino acid sequence of any one of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO:15; and provided is a pharmaceutical composition comprising a HIV fusion inhibitor pep... | 02/16/2012 |
| 20120039845 | NUCLEOSIDE PRODRUGS AND USES THEREOF Compounds having the formula I or II, wherein R1, R2, B, and V are as defined herein, are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication. 02/16/2012 | |
| 20120039978 | Novel Anti-Viral Method The invention provides a method of reducing viral infectivity in a sample compnsing contacting the sample with a earner matrix wherein lipids are attached to the carrier matrix, and wherein at least one virus-specific agent is attached to the lipids The virus-specific a... | 02/16/2012 |
| 20120034189 | MEANS AND METHODS FOR DURABLE INHIBITION OF PATHOGENS The invention provides improved nucleic acids for anti-HIV therapy. The invention further provides selection methods which are capable of predicting already at an early stage of development whether promising anti-pathogenic candidate compounds will be suitable for thera... | 02/09/2012 |
| 20120034678 | Diaryl Ethers Compounds of the formula I: including any possible stereoisomers thereof, or a pharmaceutically acceptable salt and/or solvate thereof, as well as pharmaceutical formulations and the use of compounds of formu... | 02/09/2012 |
| 20120035198 | Antiviral Compounds and Methods of Using Thereof Disclosed herein are compounds which exhibit antiviral activity against a plurality of viruses belonging to different families such as Bornaviridae, Filoviridae, Paramyxoviridae, Rhabdoviridae, Arenaviridae, Bunyaviridae, Orthomyxoviridae, and Poxviridae. Thus, methods ... | 02/09/2012 |
| 20120028887 | LIPOPEPTIDE INHIBITORS OF HIV-1 The invention provides lipophilic conjugates comprising a short isolated peptide coupled to a hydrophobic moiety, the peptide comprising a sequence derived from the HIV-1 gp41 N-terminal heptad repeat domain, said peptide after conjugation to the hydrophobic moiety poss... | 02/02/2012 |
| 20120014913 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS This disclosure is directed to: (a) processes for preparing a compound and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compound and salts; (c) pharmaceutical compositions comprisi... | 01/19/2012 |
| 20120015424 | Arginine Inactivation of Viruses The present invention pertains to methods of using arginine to inactivate or reduce the infectious titer of enveloped viruses potentially present in biological compositions produced by eukaryotic cells (such as a antibodies or other therapeutic proteins). In some embodi... | 01/19/2012 |
| 20110318352 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS The invention provides compositions, kits and methods utilizing polypeptides having a viral alpha-helix heptad repeat domain in a stabilized a-helical structure (herein also referred to as SAH). The compositions are useful for treating and/or preventing viral infections... | 12/29/2011 |
| 20110311569 | HIV-1 Peptides, Nucleic Acids, and Compositions and Uses Thereof This invention features polypeptides, variants thereof, and fragments thereof useful in eliciting an immune response (e.g., neutralizing antibodies) against abroad spectrum of HIV-I isolates. The polypeptides, variants, and fragments include a portion of the gp120 V2 do... | 12/22/2011 |
| 20110313022 | Compositions and Methods for Diminishing Viral Infection and Inflammation Associated with Viral Infection The invention relates to compositions and methods for preventing and diminishing virus infection. The invention further relates to compositions and methods for diminishing inflammation associated with viral infection. The invention also relates to compositions and metho... | 12/22/2011 |
| 20110300104 | HEPATITIS C VIRUS INHIBITORS The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the Hepatitis C Virus (HCV). Conse... | 12/08/2011 |
| 20110263535 | TYROSINE-BASED PRODRUGS OF ANTIVIRAL AGENTS A tyrosine-based (phosphonylmethoxyalkyl)purine or -pyrimidine conjugate is provided. In some embodiments, the conjugate includes tyrosine based amino acid or dipeptide moieties of (S)-9-(3-hydroxy-2-phosphonyl-methoxypropyl)adenine or its cytosine analogue. A method of... | 10/27/2011 |
| 20110250172 | HEPATITIS C VIRUS INHIBITORS The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Conse... | 10/13/2011 |
| 20110243897 | MODIFICATION OF NUCLEIC ACID VECTORS WITH POLYMERS COMPRISING CHARGED QUATERNARY AMINO GROUPS The present invention provides a polymer modified nucleic acid vector in which the nucleic acid vector is covalently linked to a polymer, which polymer comprises one or more positively charged quaternary amino groups.... | 10/06/2011 |
| 20110217330 | NOVEL METHOD The present invention relates to a method for degrading host cell nucleic acids associated with a virus or a viral antigen thereof produced by cell culture, the method comprising at least two steps of nucleic acids degradation with a compound selected from i) an endonuc... | 09/08/2011 |
| 20110212056 | COMBINATION THERAPY FOR THE TREATMENT OF LIVER DISEASES Provided herein are methods for treatment of a liver disease by administering a combination of a matrix metalloproteinase inhibitor and a caspase inhibitor. Also provided are methods for reducing liver damage associated with a liver disease by administering the MMP and ... | 09/01/2011 |
| 20110183894 | ANTIVIRAL ACTIVITY OF THE PROTEIN SCYTOVIRIN AND METHODS OF USE The present invention features methods of treating or preventing a viral infection in a subject, methods of inhibiting a virus in a biological sample, and methods of treating or preventing a viral infection caused by a virus in or on the skin or mucus membrane. The inst... | 07/28/2011 |
| 20110165120 | INHIBITORS OF SERINE PROTEASES The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4... | 07/07/2011 |
| 20110150827 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment ... | 06/23/2011 |
| 20110150929 | SARS vaccine compositions and methods of making and using them Described is a composition and method for reducing the occurrence and severity of infectious diseases, especially infectious diseases such as SARS, in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention ... | 06/23/2011 |
| 20110142798 | HEPATITIS C VIRUS INHIBITORS The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Conse... | 06/16/2011 |
| 20110136210 | USE OF METHYLSULFONYLMETHANE (MSM) TO MODULATE MICROBIAL ACTIVITY Disclosed herein are methods of use of methylsulfonylmethane (MSM) to modulate microbial activity, such as to enhance or inhibit the activity of microorganisms. In one example, MSM (such as about 0.5% to 5% MSM) is used to enhance fermentation efficiency, such as to enh... | 06/09/2011 |
| 20110129443 | MACROCYCLIC SERINE PROTEASE INHIBITORS Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infectio... | 06/02/2011 |
| 20110123496 | BISMACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS The present invention discloses compounds of formula Ia or Ib or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis ... | 05/26/2011 |
| 20110124703 | MOLECULES COMPRISING A BIS(HETEROARYL)MALEIMIDE BACKBONE, AND USE THEREOF IN THE INHIBITION OF DDE/DDD ENZYMES The invention concerns molecules with a bis-(heteroaryl)maleimide structure and having inhibiting characteristics with respect to enzymes with a catalytic pocket comprising the invariant amino acids D, D and E or D, D and D, such as transposases, RAG recombinases or ret... | 05/26/2011 |
| 20110118334 | ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING INFLUENZA VIRAL INFECTION The present invention relates to antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of ... | 05/19/2011 |
| 20110110975 | INACTIVATED VIRUS COMPOSITIONS AND METHODS OF PREPARING SUCH COMPOSITIONS The present invention is a composition comprising a live virus having an infectious component and a plurality of surface antigens in contact with a formaldehyde donor agent having a molecular weight that is less than about 400 g/mol. The present invention further provid... | 05/12/2011 |
| 20110105423 | COMPOUNDS THAT MODULATE NEGATIVE-SENSE, SINGLE-STRANDED RNA VIRUS REPLICATION AND USES THEREOF The present invention relates to compounds that modulate the replication of negative-sense, single-stranded RNA viruses, such as influenza virus, and the use of such compounds. The invention relates to methods for increasing the titer of negative-sense, single-stranded ... | 05/05/2011 |
| 20110081700 | Methods of Purifying Recombinant Adamts13 and Other Proteins and Compositions Thereof Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydr... | 04/07/2011 |
| 20110070193 | Anti-Infective Agents and Uses Thereof This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compou... | 03/24/2011 |
| 20110070196 | HEPATITIS C VIRUS INHIBITORS The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Conse... | 03/24/2011 |
| 20110070197 | HEPATITIS C VIRUS INHIBITORS The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Conse... | 03/24/2011 |
| 20110064697 | HEPATITIS C VIRUS INHIBITORS The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Conse... | 03/17/2011 |
| 20110059040 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL AND BACTERIAL ACTIVITY Described herein are methods of inhibiting the activity of a virus or a bacterium comprising contacting a virus or bacterium with a polymer functionalized with at least one boronic acid moiety. Also described are methods of treatment using such functionalized polymers.... | 03/10/2011 |
| 20110046982 | METHODS AND COMPOSITIONS RELATED TO VIRAL INHIBITION Disclosed herein are compounds, compositions and methods related to viral inhibition. In some forms, the compounds, compositions and methods are related to binding RNA.... | 02/24/2011 |
| 20110045103 | METHODS FOR TREATING AIDS The present invention pertains to methods of inactivating human immunodeficiency virus (HIV), both in vitro and in vivo. Such methods also relate to treating HIV-related symptoms and the treatment of acquired immune deficiency syndrome in patients. Methods typically emp... | 02/24/2011 |
| 20110038890 | Cellular And Viral Inactivation The invention involves inactivation of viral populations by treating the viral populations with a compound to crosslink proteins in the viral membrane, UV irradiation and further inactivation of the viruses using detergent(s). According to the invention, this method pre... | 02/17/2011 |
